This webinar will focus on the specific challenges of creating assets for the manufacture of ATMP therapeutics whose success hinges upon how well this cutting-edge science translates into facility and process design.
The beauty of mRNA vaccines is their ability to be quickly updated. Though the vaccine makers are confident in their original vaccines, as COVID-19 continues to change, the vaccines can change, too.
